Myriad Genetics (MYGN) investor relations material

Key drivers and financial performance

• Q2 revenues declined 11% and average selling prices (ASPs) fell 9%, prompting reduced guidance.

• Main challenges were softness in prenatal testing and reimbursement pressure in hereditary cancer testing.

• Guidance is set conservatively, assuming no improvement in ASPs or contribution from new sales hires or products in H2.

• Revenue cycle management and payer alignment initiatives are underway to address reimbursement friction.

• Liquidity at end of Q2 was $190 million, with a focus on cash preservation and targeted investment in cancer care.

Strategic initiatives and operational changes

• Project Ascend aims to modernize operations, improve productivity, and scale for the future, with initial benefits expected in 2027 and further actions into 2028.

• Portfolio review prioritizes the cancer care continuum, with decisions on investment, divestment, and partnerships expected in the coming months.

• Cost reduction and revenue synergy are both targeted through process optimization and holistic organizational review.

Product and market updates

• MyRisk hereditary cancer testing continues strong volume growth, driven by new products, dedicated sales teams, and updated clinical guidelines.

• Early access for MRD (minimal residual disease) tests in breast, colorectal, and renal cancers shows positive customer feedback and operational efficiency; reimbursement for breast expected in H1 2027.

• FirstGene prenatal test launched, showing early positive feedback and higher ASPs than legacy products, but not yet material to guidance.

• GeneSight mental health test maintains market leadership and volume growth, with ASP improvements driven by payer engagement and biomarker legislation.

• Prolaris + AI test for prostate cancer is gaining interest, especially for active surveillance decisions, and is expected to help regain market share.